CervoMed (NASDAQ:CRVO - Get Free Report) issued its earnings results on Monday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.13), Zacks reports. The company had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.
CervoMed Trading Up 23.6 %
Shares of CervoMed stock traded up $2.73 during midday trading on Friday, reaching $14.29. The company had a trading volume of 7,288,342 shares, compared to its average volume of 1,209,310. The stock has a fifty day simple moving average of $3.06 and a 200 day simple moving average of $7.90. CervoMed has a 1-year low of $1.80 and a 1-year high of $25.92. The company has a market capitalization of $88.17 million, a price-to-earnings ratio of -7.04 and a beta of 1.84.
Analyst Ratings Changes
Several research analysts have issued reports on CRVO shares. D. Boral Capital reiterated a "buy" rating and set a $10.00 price objective on shares of CervoMed in a research note on Monday. Canaccord Genuity Group increased their target price on shares of CervoMed from $12.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday. Chardan Capital upgraded shares of CervoMed from a "neutral" rating to a "buy" rating and set a $14.00 price target on the stock in a research report on Thursday, March 13th. Roth Capital raised shares of CervoMed to a "strong-buy" rating in a report on Thursday, December 5th. Finally, Brookline Capital Management raised CervoMed from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $27.50.
Check Out Our Latest Analysis on CRVO
About CervoMed
(
Get Free Report)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Recommended Stories
Before you consider CervoMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.
While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
